Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

AKTS stock hub

Aktis Oncology, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

AKTSis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

AKTS

In the news

Latest news · AKTS

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-29.4

P25 -105.6P50 -46.5P75 -3.1

ROIC-20.5

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All AKTS market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

167

Groups with data

Currency

USD

Showing 167 of 167 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0002035832
Company name	Aktis Oncology, Inc.
Country	United States
Country code	US
Cusip	01021M104
Employees	79
Enterprise value	$812.9M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2026-01-09
Isin	US01021M1045
Last refreshed	2026-05-10
Market cap	$1B
Market cap category	Small-Cap
Price	$18.6
Price currency	USD
Rev Per Employee	82,240.51x
Sector	Healthcare
Sic	2834
Symbol	AKTS
Website	https://www.aktisoncology.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-6.2%
EV Sales Forward	40.61x
EV/Sales	125.12x
FCF yield	-7.17%
P/B ratio	5.49x
P/S ratio	158.25x
PS Forward	51.36x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross Profit	$-61M
Net Income	$-63.7M
Net Income Growth Years	0%
Pretax Margin	-980.93%
Profit Per Employee	$-806,722
ROA	-15.79
ROCE	-31.96
ROE	-29.45
ROIC	-20.45

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS Growth Years	0
Revenue Growth	336.92x
Revenue Growth Years	1x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.02
Assets	$264.9M
Cash	$226.8M
Current Assets	$230.3M
Current Liabilities	$31.2M
Debt	$11.5M
Debt Equity	$0.06
Equity	$187.3M
Liabilities	$77.6M
Long Term Assets	$34.6M
Long Term Liabilities	$46.4M
Net Cash	$215.2M
Net Cash By Market Cap	$20.93
Net Debt Equity	$-1.15
Tangible Book Value	$-146.1M
Tangible Book Value Per Share	$-160

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	7.37
Net Working Capital	$-26.4M
Quick ratio	7.3
Working Capital	$199.1M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-32.24%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
50-day SMA	18.81
All Time High	29.16
All Time High Change	-36.21%
All Time High Date	2026-01-09
All Time Low	14.72
All Time Low Change	26.36%
All Time Low Date	2026-03-30
ATR	1.41
Beta1y	2.75
High	19.12
High52	29.16
High52 Date	2026-01-09
High52ch	-36.21%
Low	18.4
Low52	14.72
Low52 Date	2026-03-30
Low52ch	26.36%
Ma50ch	-1.09%
RSI	46.92
RSI Monthly	0
RSI Weekly	43.93
Sharpe ratio	-0.55x
Sortino ratio	-0.68
Total Return	-32.24%
Tr1m	11.24%
Tr1w	-4.22%
Tr3m	-2%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	3
Analyst Count Top	2
Analyst Price Target Top	$31.5
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.33
Earnings Revenue Estimate	2,068,000x
Earnings Revenue Estimate Growth	-77.09x
Operating Income	$-74.7M
Operating margin	-1,149.5
Price target	$31.5
Price Target Change	$69.36
Price Target Change Top	$69.36

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	26,364,938%
Float Percent	47.7%
Shares Insiders	0.46%
Shares Institutions	15.37%
Shares Out	55,276,002
Shares Qo Q	10.72%
Shares Yo Y	32.24%
Short Float	8.88%
Short Ratio	4.24
Short Shares	4.24

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-78.8M
Average Volume	222,564.95x
Bv Per Share	-159.7
CAPEX	$-9.6M
Ch1m	11.24
Ch1w	-4.22
Ch3m	-2
Change	-1.27%
Change From Open	-1.06
Close	18.84
Days Gap	-0.21
Depreciation Amortization	2,329,000
Dollar Volume	2,187,694.8
Earnings Date	2026-05-15
Earnings Time	bmo
EBIT	$-74.7M
EBITDA	$-72.4M
EPS	$-78.34
F Score	0
FCF	$-73.7M
FCF EV Yield	-9.07x
FCF Per Share	$-1.33
Financing CF	-1,212,000
Fiscal Year End	December
Founded	2,020
Investing CF	65,964,000
Ipr	3.33
Iprfo	-31.11
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2024-11-14
Last Report Date	2025-12-31
Last Split Type	Never
Last10k Filing Date	2026-03-30
Ma20	19.51
Ma20ch	-4.68%
Net CF	625,000
Next Earnings Date	2026-05-22
Open	18.8
Optionable	No
Position In Range	27.78
Post Close	18.6
Postmarket Change Percent	-0.54
Postmarket Price	$18.5
Ppne	27,246,000
Price Date	2026-05-08
Relative Volume	0.53x
Revenue	6,497,000x
SBC By Revenue	78.97x
Share Based Comp	5,131,000
Us State	Massachusetts
Volume	117,618
Z Score	-0.83

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does AKTS pay a dividend?

Capital-return profile for this ticker.

Ownership

Who owns AKTS?

Insider, institutional, and short-interest positioning.

Institutional ownership

+15.4%

Float: +47.7% of shares outstanding

Insider ownership

+0.5%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

AKTS momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

46.9

Neutral momentum band

Price vs 200-day MA

n/a

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

-0.55

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About AKTS

Hub-level FAQ points readers to the deeper analysis pages.

What is the current AKTS stock rating?

Aktis Oncology, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full AKTS analysis?

The full report lives at /stocks/AKTS/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for AKTS?

The latest report frames AKTS around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the AKTS page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.